Source: China – South China Morning PostChina is accelerating research into vaccines and tests to cope with possible future Omicron variant outbreaks amid global concern about its potential damage.Sino Biological, a Beijing-based company specialising in recombinant protein production, antibody development and the manufacture of test reagents, announced on Thursday it had developed a key part of the recombinant spike protein of the Omicron variant that could be used to test the efficacy of Covid-19 vaccines and antibodies.Most…Read More